Sangamo Therapeutics, INC 8-K filings

Sangamo Therapeutics has been notified by Nasdaq that its stock price has fallen below the minimum required bid price of $1.00 per share for continued listing.

Sangamo Therapeutics has entered into a securities purchase agreement to raise approximately $24 million through a registered direct offering of common stock and warrants.

Sangamo Therapeutics announced its full year 2023 financial results and highlighted advancements in its neurology pipeline, including promising preclinical data for its novel AAV capsid delivery technology.

Sangamo Therapeutics reported updated positive preliminary clinical data from its Phase 1/2 STAAR study of isaralgagene civaparvovec for Fabry disease, showing sustained enzyme activity and clinical improvements.

Sangamo Therapeutics' board decided against awarding 2023 bonuses to executive officers and established a retention program tied to successful capital raising.